The BENEFIT trial: Isa-VRd in non-frail patients with NDMM TI

At the EHA 2024 conference, Prof Dr Xavier Leleu, Head of the Myeloma Clinic and Department of Haematology at the University Hospital of Poitiers (France), presented the results of the BENEFIT trial. BENEFIT is a prospective, multicenter, randomised study designed to evaluate the efficacy and safety of the IsaRd regimen versus the Isa-VRd regimen in non-frail, NDMM TI patients aged 65-79 years. The primary endpoint, MRD at a sensitivity of 10^-5 at 18 months from the start of treatment, was significantly higher in the Isa-VRd arm compared to the IsaRd arm. Additionally, MRD at a sensitivity of 10^-6 at 18 months was superior in the Isa-VRd cohort relative to the IsaRd arm, with benefits observed as early as 12 months into treatment.

The safety profile was consistent with the addition of bortezomib. These findings suggest that the Isa-VRd regimen should be considered a new standard of care for non-frail patients with NDMM TI.